These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36198529)

  • 1. [Novel therapies in AML and their resistance mechanisms].
    Takahashi K
    Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
    Yilmaz M; Daver N
    Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
    Gebru MT; Wang HG
    J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance in mutant FLT3-positive AML.
    Weisberg E; Sattler M; Ray A; Griffin JD
    Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 inhibitors in AML: are we there yet?
    Sudhindra A; Smith CC
    Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin approved for FLT3-mutated AML.
    Levis M
    Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
    Grunwald MR; Levis MJ
    Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapies for acute myeloid leukemia.
    Stein EM
    Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
    Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
    Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine in AML: overcoming resistance.
    Urrutia S; Takahashi K
    Int J Hematol; 2024 Oct; 120(4):439-454. PubMed ID: 39085680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in molecularly targeted therapies for acute myeloid leukemia].
    Tomita A
    Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
    Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.